Santen Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	78,258	80,875	92,997	94,582	57,903	83,014
Cash & Short-Term Investments	78,258	80,875	92,997	94,582	57,903	83,014
Cash Growth	-7.47%	-13.04%	-1.68%	63.35%	-30.25%	32.00%
Accounts Receivable	63,320	71,754	71,759	90,539	107,165	99,591
Other Receivables	287	76	324	-	60	-
Receivables	63,607	71,830	72,083	90,539	107,225	99,591
Inventory	65,072	64,584	51,590	43,185	39,352	37,141
Other Current Assets	12,912	11,469	7,630	7,833	8,846	9,680
Total Current Assets	219,849	228,758	224,300	236,139	213,326	229,426
Property, Plant & Equipment	80,292	78,115	72,954	71,576	66,173	56,287
Long-Term Investments	-	33,658	26,539	33,400	42,560	40,944
Goodwill	-	9,360	8,242	8,303	7,385	13,715
Other Intangible Assets	71,792	62,298	67,225	75,516	88,924	116,502
Long-Term Deferred Tax Assets	10,340	10,843	10,017	10,765	2,810	3,103
Other Long-Term Assets	33,576	1	-	-	1	-1
Total Assets	415,849	423,033	409,277	435,699	421,179	459,976
Accounts Payable	27,185	35,350	38,989	43,531	44,945	41,185
Accrued Expenses	-	8,180	6,514	7,792	-	-
Short-Term Debt	-	306	274	54	245	10,936
Current Portion of Leases	-	3,227	3,015	2,694	2,811	3,029
Current Income Taxes Payable	2,072	6,272	3,029	5,710	6,745	4,198
Other Current Liabilities	48,821	34,533	35,016	33,015	34,758	36,473
Total Current Liabilities	78,078	87,868	86,837	92,796	89,504	95,821
Long-Term Debt	-	27,336	26,483	26,915	28,198	12,677
Long-Term Leases	-	3,883	4,457	4,947	4,953	6,290
Pension & Post-Retirement Benefits	1,219	1,424	1,221	1,292	1,271	1,077
Long-Term Deferred Tax Liabilities	4,049	4,338	2,606	1,377	1,592	2,526
Other Long-Term Liabilities	33,233	2,167	2,492	3,002	2,365	4,742
Total Liabilities	116,579	127,016	124,096	130,329	127,883	123,133
Common Stock	8,830	8,824	8,806	8,777	8,702	8,672
Additional Paid-In Capital	9,736	9,595	9,797	9,854	9,789	9,370
Retained Earnings	224,482	223,285	228,291	240,029	238,071	290,477
Treasury Stock	-1,934	-979	-1,161	-1,018	-364	-718
Comprehensive Income & Other	59,149	56,264	40,509	48,413	37,781	29,687
Total Common Equity	300,263	296,989	286,242	306,055	293,979	337,488
Minority Interest	-993	-972	-1,061	-685	-683	-645
Shareholders' Equity	299,270	296,017	285,181	305,370	293,296	336,843
Total Liabilities & Equity	415,849	423,033	409,277	435,699	421,179	459,976
Total Debt	-	34,752	34,229	34,610	36,207	32,932
Net Cash (Debt)	78,258	46,123	58,768	59,972	21,696	50,082
Net Cash Growth	-7.47%	-21.52%	-2.01%	176.42%	-56.68%	-5.04%
Net Cash Per Share	243.65	140.46	168.06	162.91	56.00	125.06
Filing Date Shares Outstanding	321.19	321.69	337.56	356.09	369.88	393.3
Total Common Shares Outstanding	321.19	321.68	341.36	363.21	375.54	400.27
Working Capital	141,771	140,890	137,463	143,343	123,822	133,605
Book Value Per Share	934.84	923.25	838.52	842.64	782.82	843.15
Tangible Book Value	228,471	225,331	210,775	222,236	197,670	207,271
Tangible Book Value Per Share	711.33	700.48	617.45	611.87	526.36	517.83